Innovative solutions

Expanding drug development capabilities to better solve your biggest challenges

$2.3 billion

Average cost of developing a new drug rose to $2.3 billion in 2022, making the CDMO partner you choose a critical investment1



Drug developers face an increasingly complex landscape. The pipeline has become more complex, with double-digit growth for specialty drugs such as biologics, orphan drugs, and cell and gene therapies. More therapies—including large molecule drugs, small molecule drugs, and advanced therapies—are also following expedited approval processes. Returns on research and development are declining, driving an urgent need for speed, efficiency, and effectiveness. Success rests upon expertise, agility, and capacity.

We are responding with innovations and investments to expand our expertise, capacity, and capabilities from early phase to commercialization. Our aim is to enhance your productivity and scalability—whether you’re an emerging biotech working on a vaccine for a novel virus or a high-volume pharmaceutical manufacturer delivering necessary drugs at scale. 

The medicines we develop and deliver to our customers help patients every day. With an increasing demand for our services, expertise and capabilities, comes a commitment to continuously expand our products and services. That's why we have been making unprecedented investments in our network of sites and capabilities around the world.


Our new Bioprocessing Collaboration Center (BCC) in St. Louis, MO, combines industry-leading expertise in single-use technologies and biologics product development and manufacturing.   

Advanced therapies 

We recently expanded our viral vector development and manufacturing capabilities in the United States, opening a new site in Lexington, MA, and expanding sites in Cambridge, MA, and Alachua, FL. We’re also building a new viral vector manufacturing facility in Plainville, MA. In Europe, we acquired Henogen in early 2021, including sites in Seneffe, Belgium, and Gosselies, Belgium, for clinical and commercial manufacturing of viral vectors. And our Monza, Italy, and Ferentino, Italy, sites are being expanded, along with our Swindon, U.K. location, to add cGMP commercial production lines.

... Read more

We are also expanding our global network and capabilities in cGMP plasmid manufacturing for clinical and commercial needs with our new site in Carlsbad, CA, and cell and gene therapy to support increasing demand for new novel medicines.

Our plans for 2022 also include the new Cell Therapy cGMP Manufacturing and Collaboration Center with the University of California, San Francisco. 

In addition to site expansions, we are adding to our solutions with translational services—custom molecular biology, viral vector packaging, and cell therapy services that use established scalable processes with advanced analytical testing representative of future cGMP workflows.

... Read less

Digital supply chain

Across the supply chain, we’re making improvements to provide you with fast, real-time access to information, anchored by our mysupply Platform,* which provides timely visibility and real-time collaboration to enable more efficient ways of working, from day-to-day order management and batch tracking to monthly forecasting.

Additionally, we are making it easier for you to see our facilities—from the inside out—through virtual site tours.

*Note, this is only launched for one business at present, with plans to expand more broadly across 2022.


Patheon pharma services is increasing our steriles capacity in several parts of the world to support our clients, including projects in Asia-Pacific such as a new sterile manufacturing facility in Singapore. We’re also working arm-in-arm with industry innovators, government agencies, and academic institutions to provide scale, flexibility, and expertise in the battle against COVID-19.

Clinical supply chain

We are expanding our integrated clinical supply chain network with initiatives such as the opening of our state-of-the-art pharma services supply chain facility in Rheinfelden (Baden), Germany, which features the latest technology and modern infrastructure to significantly increase European capacity for cold and ambient clinical trial materials. We are also investing in direct-to-patient patient services to deliver improved patient engagement and retention through flexible, decentralized trial service options designed to fit the trial format to patient needs.

Continuous manufacturing

To ensure quality and consistency, reap the benefits of continuous manufacturing. This innovative solution provides flexibility and cost savings within your oral solid dose drug manufacturing by minimizing API usage, shortening development timelines, reducing total cost of ownership, and more.

To support continuous innovations and investments, we have assembled a global team with unmatched collective expertise. Our integrated network of scientific, technical, quality, and customer engagement experts is ready to support your entire drug development journey, wherever your operations are located.

Discover our end-to-end solutions

Digital enablement

To help our clients meet the demands of the increasingly digital world, we are responding with innovations that push the limits of efficiency, agility, and quality for our customers as we adopt networked systems, data analytics, and advanced automation. Offerings such as our mysupply digital supply chain platform and direct-to-patient decentralized trial services are paving the way forward.

Integrated offerings

We use a seamless one-team approach to deliver the power of our full network. The Patheon™ Quick to Clinic™ program is designed to accelerate your early development speed while using a proven process platform—for biologics, small molecules, and viral vector services. We streamline your drug substance and drug product development, demand planning and clinical trial supply execution into a single customized solution with our Patheon™ Quick to Care™ program.


The growing market demands a shift in capacity, driven by advances in bioprocesses and capabilities—as well as a focus on smaller, niche populations. Our innovative manufacturing solutions include continuous manufacturing, where we move materials non-stop through an integrated equipment train to eliminate the hold times between processing steps. The result is reduced API usage and shorter timelines.

Supply chain and speed to market

Maintaining supply chain continuity has never been more critical, and pharma companies everywhere are exploring ways to increase efficiency. We protect product integrity throughout your supply chain or cold chain with our world-class total transportation management, storage, and distribution services. Our global expertise in technology transfers can help you quickly and reliably scale up production or shift production between sites.

View references
1. Measuring the return from pharmaceutical innovation 2022 — Deloitte's thirteenth annual report from the Deloitte Centre for Health Solutions.